Skip to main content
. 2013 Aug 14;2(8):e64. doi: 10.1038/psp.2013.42

Figure 4.

Figure 4

Predicted probability of success (VL <50 copies/ml) at week 48 using the final generalized additive model (Model 8 in Table 2) in patients from the MOTIVATE studies. Top row is by TRT group and TRT2 group, bottom row is by BLQ category. b.i.d., twice daily; BLQ, below the limit of quantification; MVC, maraviroc; q.d., once daily; TRT, treatment group: placebo, MVC q.d., MVC b.i.d.; TRT2, treatment group: placebo, MVC q.d. and b.i.d. combined; VL, viral load.